Dhtml Menu Css by v5.7
Liang Xu, M.D., Ph.D.

Liang Xu, M.D., Ph.D.
Research Assistant Professor, Department of Radiation Oncology, Division of Cancer Biology, University of Michigan Comprehensive Cancer Center


Dr. Xu's laboratory has been working on tumor-targeted delivery of molecular cancer therapeutics using novel nanotechnology. A self-assembled, virus-mimicking, non-viral nanovector for systemic p53 gene therapy has shown promise in chemo- and radiosensitization of breast, prostate, head and neck cancer, is now in Phase I clinical trial. Dr. Xu's laboratory has been involved in discovering novel small-molecule cancer therapeutics targeting cell death pathways, especially for cancer cell radiosensitization and chemosensitization by molecular modulation of anti-apoptotic proteins. Multiple US and International Patents are issued or pending. One of the first lead compounds tested extensively in vitro and in vivo in his laboratory has entered Phase I-II clinical trials as the World's first small-molecule inhibitor of Bcl-2/Bcl-xL in clinic. Currently, Dr. Xu is using his patented nanovector for tumor-targeted delivery of siRNA-based therapeutics and novel small-molecule therapeutics. His lab is also working with University of Michigan Cancer Stem Cell Group to explore next generation nanovectors for targeting cancer stem cells.



© The Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS)® 2010
MNIMBS is a registered trademark of The Michigan Nanotechnology Institute for Medicine and Biological Sciences.
MNIMBS logo and graphic designed by Paul D. Trombley, website by Mellon & Associates, LLC
All other company, brand, and product names are or may be trademarks of their respective holders.